Treatment of anaemia in end-stage renal disease: A double-edged iron sword?
作者信息
Chinnadurai Rajkumar, Macdougall Iain C, Kalra Philip A
机构信息
Department of Renal Medicine, Salford Royal NHS Foundation Trust, Salford, United Kingdom.
Department of Renal Medicine, King's College Hospital, London, United Kingdom.
出版信息
EBioMedicine. 2019 Feb;40:31-32. doi: 10.1016/j.ebiom.2019.01.005. Epub 2019 Jan 17.
Abstract
摘要
相似文献
1
Treatment of anaemia in end-stage renal disease: A double-edged iron sword?终末期肾病贫血的治疗：一把双刃剑？
EBioMedicine. 2019 Feb;40:31-32. doi: 10.1016/j.ebiom.2019.01.005. Epub 2019 Jan 17.
2
Management of anemia.贫血的管理
Contrib Nephrol. 2004;145:69-74. doi: 10.1159/000081670.
3
New developments in anemia management in chronic kidney disease.慢性肾脏病贫血管理的新进展
Nephrol News Issues. 2008 Mar;22(3):suppl 1-8.
4
Renal Association Clinical Practice Guideline on anaemia of chronic kidney disease.肾脏协会慢性肾脏病贫血临床实践指南。
Nephron Clin Pract. 2011;118 Suppl 1:c101-24. doi: 10.1159/000328063. Epub 2011 May 6.
5
Management of the anaemia of chronic renal failure with recombinant erythropoietin.重组促红细胞生成素治疗慢性肾衰竭贫血
Q J Med. 1989 Dec;73(272):1093-101.
6
Anemia of chronic renal failure.慢性肾衰竭贫血
JAMA. 1971 Mar 22;215(12):1987.
7
[Management of renal anemia in 2013].《2013年肾性贫血的管理》
Rev Med Suisse. 2013 Feb 27;9(375):462-4, 466-7.
8
[Favourable effects of the treatment of renal anemia in early stage chronic renal failure].[早期慢性肾衰竭肾性贫血治疗的有利作用]
Lijec Vjesn. 2002 Mar-Apr;124(3-4):108-9.
9
The use of IV iron in the treatment of anaemia of ESRD patients on maintenance haemodialysis: an historical and personal view.静脉注射铁剂在维持性血液透析的终末期肾病患者贫血治疗中的应用：历史回顾与个人观点。
Nephrol Dial Transplant. 2007 Jan;22(1):23-5. doi: 10.1093/ndt/gfl639. Epub 2006 Nov 6.
10
[Renal anemia and thrombopathy].[肾性贫血与血栓形成异常]
Verh Dtsch Ges Inn Med. 1974;80:625-8.
引用本文的文献
1
INFERR-Iron infusion in haemodialysis study: INtravenous iron polymaltose for First Nations Australian patients with high FERRitin levels on haemodialysis-a protocol for a prospective open-label blinded endpoint randomised controlled trial.INFER-铁剂输注血液透析研究：血液透析高铁蛋白水平的原住民澳大利亚患者的静脉铁多聚糖治疗：一项前瞻性开放标签设盲终点随机对照试验方案。
Trials. 2021 Dec 2;22(1):868. doi: 10.1186/s13063-021-05854-w.
2
Narrative Review of Hyperferritinemia, Iron Deficiency, and the Challenges of Managing Anemia in Aboriginal and Torres Strait Islander Australians With CKD.澳大利亚原住民和托雷斯海峡岛民慢性肾脏病患者高铁蛋白血症、缺铁及贫血管理挑战的叙述性综述
Kidney Int Rep. 2020 Nov 10;6(2):501-512. doi: 10.1016/j.ekir.2020.10.035. eCollection 2021 Feb.
3
Histological Scores Validate the Accuracy of Hepatic Iron Load Measured by Signal Intensity Ratio and R2* Relaxometry MRI in Dialysis Patients.组织学评分验证了通过信号强度比和R2*弛豫测量MRI测量的透析患者肝铁负荷的准确性。
J Clin Med. 2019 Dec 19;9(1):17. doi: 10.3390/jcm9010017.
4
Risk of iron overload with chronic indiscriminate use of intravenous iron products in ESRD and IBD populations.终末期肾病（ESRD）和炎症性肠病（IBD）人群长期不加区分地使用静脉铁剂产品导致铁过载的风险。
Heliyon. 2019 Jul 12;5(7):e02045. doi: 10.1016/j.heliyon.2019.e02045. eCollection 2019 Jul.
5
Mechanism of Action and Clinical Attributes of Auryxia (Ferric Citrate).Auryxia（柠檬酸铁）的作用机制和临床特征。
Drugs. 2019 Jun;79(9):957-968. doi: 10.1007/s40265-019-01125-w.
本文引用的文献
1
Liver Iron Load Influences Hepatic Fat Fraction in End-Stage Renal Disease Patients on Dialysis: A Proof of Concept Study.肝脏铁负荷影响透析终末期肾病患者的肝脂肪分数：概念验证研究。
EBioMedicine. 2019 Jan;39:461-471. doi: 10.1016/j.ebiom.2018.11.020. Epub 2018 Nov 28.
2
Intravenous Iron in Patients Undergoing Maintenance Hemodialysis.维持性血液透析患者的静脉铁剂治疗。
N Engl J Med. 2019 Jan 31;380(5):447-458. doi: 10.1056/NEJMoa1810742. Epub 2018 Oct 26.
3
Non-alcoholic fatty liver disease and clinical outcomes in chronic kidney disease.非酒精性脂肪性肝病与慢性肾脏病的临床转归。
Nephrol Dial Transplant. 2019 Mar 1;34(3):449-457. doi: 10.1093/ndt/gfx381.
4
Association of non-alcoholic fatty liver disease with major adverse cardiovascular events: A systematic review and meta-analysis.非酒精性脂肪性肝病与主要不良心血管事件的关联：系统评价和荟萃分析。
Sci Rep. 2016 Sep 16;6:33386. doi: 10.1038/srep33386.
5
Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis.非酒精性脂肪性肝病与心血管疾病发病风险：荟萃分析。
J Hepatol. 2016 Sep;65(3):589-600. doi: 10.1016/j.jhep.2016.05.013. Epub 2016 May 17.
6
Iron management in chronic kidney disease: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference.慢性肾脏病中的铁管理：“改善全球肾脏病预后组织”（KDIGO）争议会议的结论。
Kidney Int. 2016 Jan;89(1):28-39. doi: 10.1016/j.kint.2015.10.002.
7
Emerging Liver-Kidney Interactions in Nonalcoholic Fatty Liver Disease.非酒精性脂肪性肝病中的新兴肝-肾相互作用。
Trends Mol Med. 2015 Oct;21(10):645-662. doi: 10.1016/j.molmed.2015.08.005.
8
Iron supplementation and mortality in incident dialysis patients: an observational study.补铁与新发透析患者死亡率：一项观察性研究。
PLoS One. 2014 Dec 2;9(12):e114144. doi: 10.1371/journal.pone.0114144. eCollection 2014.
9
Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis.非酒精性脂肪性肝病与慢性肾脏病的关联：一项系统评价和荟萃分析
PLoS Med. 2014 Jul 22;11(7):e1001680. doi: 10.1371/journal.pmed.1001680. eCollection 2014 Jul.
10
Association between hemoglobin variability, serum ferritin levels, and adverse events/mortality in maintenance hemodialysis patients.维持性血液透析患者血红蛋白变异性、血清铁蛋白水平与不良事件/死亡率的关系。
Kidney Int. 2014 Oct;86(4):845-54. doi: 10.1038/ki.2014.114. Epub 2014 Apr 23.
Zotero 插件